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ABSTRACT 
Introduction. Azithromycin has modest efficacy against malaria, and previous cluster 
randomized trials have suggested that mass azithromycin distribution for trachoma control may 
play a role in malaria control. We evaluated the effect of annual versus biannual mass 
azithromycin distribution over a three-year period on malaria prevalence during the peak 
transmission season in a region with seasonal malaria transmission in Niger.  
Methods. Twenty-four communities in Matamèye, Niger were randomized to annual mass 
azithromycin distribution (3 distributions to the entire community during the peak transmission 
season) or biannual targeted azithromycin distribution (6 distributions to children <12 years, 
including 3 in the peak transmission season and 3 in the low transmission season). Malaria 
indices were evaluated at 36 months during the high transmission season. 
Results. Parasitemia prevalence was 42.6% (95% confidence interval [CI] 31.7 to 53.6%) in the 
biannual distribution arm compared with 50.6% (95% CI 40.3 to 60.8%) in the annual 
distribution arm (P=0.29). There was no difference in parasite density or hemoglobin 
concentration in the two treatment arms.  
Conclusions. Additional rounds of mass azithromycin distribution during low transmission may 
not have a significant impact on malaria parasitemia measured during the peak transmission 
season. 
Trial Registration. clinicaltrials.gov NCT00792922 
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INTRODUCTION 
 Studies of mass azithromycin for trachoma control have suggested that azithromycin may 
play a role in malaria control.1,2 Azithromycin has activity against the apicoplast, an organelle 
that is required for plasmodium survival.3-6 Although it has been shown to be inferior to other 
antimalarial treatment options as first-line treatment, azithromycin is known to be safe for mass 
distribution, with millions of doses distributed annually as part of trachoma control programs.7,8 
Mass azithromycin distribution for trachoma control has been shown to significantly decrease 
child mortality, an effect which may be partially mediated by reduction in infection burden.9 
Azithromycin has also been safely and effectively used as part of combination treatment 
strategies for the prevention of malaria in pregnant women.10 Even though azithromycin 
monotherapy is not recommended for the treatment of malaria at the individual level, mass 
azithromycin distribution in malaria endemic regions could be beneficial if it reduces the malaria 
burden in communities.  
 Two previous substudies of a randomized controlled trial of mass azithromycin 
distribution for trachoma control in Niger found conflicting results comparing annual and 
biannual mass azithromycin for malaria.1,11 Compared with a single mass azithromycin 
distribution, two mass azithromycin distributions (6 months apart) was shown to lead to a 
significant reduction in malaria parasitemia.1 However, there was no significant difference in 
malaria prevalence or parasitemia during the high transmission season between three annual 
compared with six biannual mass azithromycin distributions in a different set of communities.11 
Here, we report 36-month malaria parasitemia outcomes from the same trial collected during the 
peak transmission season after 3 annual or 6 biannual azithromycin distributions in the same 
communities in which a decrease in parasitemia prevalence was previously noted during the low 
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transmission season following two mass azithromycin distributions compared with a single mass 
azithromycin distribution. 
METHODS 
Study design. The Partnership for the Rapid Elimination of Trachoma (PRET) was a consortium 
of community-randomized trials conducted in Niger, The Gambia, and Tanzania 
(clinicaltrials.gov NCT00792922) comparing mass azithromycin distribution strategies for 
trachoma control. Complete methods for the PRET study have been reported previously.12,13 The 
present report focuses solely on the Niger trial, which enrolled participants in Matamèye District, 
Zinder Region between May 2010 and August 2013. Communities were randomized to one of 
four arms in a 2x2 factorial design: 1) annual treatment of all individuals in the community with 
a treatment coverage target of 80%; 2) annual treatment of all individuals in the community with 
a treatment coverage target of >90%; 3) biannual treatment of children aged 12 and under with a 
treatment coverage target of 80%; or 4) biannual treatment of children aged 12 and under with a 
treatment coverage target of >90%. Here, we report outcomes comparing annual versus biannual 
distribution with treatment coverage targets of 80% (the standard WHO treatment coverage 
target for trachoma control). Communities were eligible for enrollment in the trial if they had a 
population between 250 and 600 at the most recent government census and clinical trachoma 
prevalence of at least 10% at the time of this census. Twenty-four grappes (henceforth, 
“community”) from 6 Centres de Santé Intégrées (CSI; larger government health unit) are 
included in this analysis.  
Ethical approval was obtained from the Committee on Human Research at the University 
of California, San Francisco and the Comité d’Ethique du Niger (the Ethical Committee of 
Niger). Given low literacy rates in the study area, both institutional review boards approved 
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verbal informed consent from local chiefs of each study community prior to randomization, and 
verbal informed consent from the parent or guardian of each participant. 
Study Setting. This study was conducted in Matemèye District, Zinder Region, Niger, which is 
situated in the Sahel of sub-Saharan Africa and has a highly seasonal malaria epidemic.14,15 The 
region is holoendemic for malaria, and cases peak shortly after the peak rainfall, typically in 
September.15 At the time of the study, the only programmatic activity ongoing in the region for 
malaria control was bednet distribution. There was no seasonal malaria chemoprevention 
program in this region at the time of the study. Individuals who self-referred for treatment to 
their local health post were treated or referred elsewhere for treatment.  
Randomization. Communities were randomized by stratified block randomization within each 
CSI by high or low clinical trachoma prevalence in the community. Communities were 
categorized as high or low trachoma prevalence based on whether they were above or below the 
median trachoma prevalence in a given CSI. The random allocation sequence was generated by 
TCP using the statistical package R (version 2.12; R Foundation for Statistical Computing, 
Vienna, Austria; www.r-project.org). 
Intervention. In the annual mass azithromycin distribution arm, all individuals aged 6 months 
and older in all communities were offered one mass azithromycin distribution per year. In the 
biannual mass azithromycin distribution arm, children aged 6 months to 12 years in all 
communities were offered two mass azithromycin distributions at approximately 6 month 
intervals: once during the low and once during the high transmission season. Enrolled children 
under 6 months of age in both groups and those allergic to macrolides were offered topical 
tetracycline ointment (1%) to be applied to both eyes (unobserved) twice a day for six weeks. 
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Target antibiotic coverage in both arms was 80%, the WHO standard for trachoma control 
programs. 
Clinical and laboratory assessments. Blood samples for determination of malaria prevalence 
were collected from a random sample of children in both arms at 36 months after baseline. 
Children were randomly selected from an annual census that was conducted prior to the annual 
treatment in each community. Blood samples were collected in September 2013, during the high 
transmission season for malaria.15,16 A target sample of 50 children randomly selected from each 
village was used for collection of blood samples for thick smear and hemoglobin assessment. In 
communities with fewer than 50 children, blood samples were collected from all children in the 
community. Thick blood smears were collected on glass slides, air-dried, and stored at room 
temperature. Each thick blood smear was stained and examined by two microscopists masked to 
each other at Zinder Regional Hospital in Niger with 3% Giemsa who determined the presence 
or absence of Plasmodium parasites on the slides. Each microscopist independently counted the 
number of asexual parasites per 200 white blood cells to assess parasite density, and the median 
of these two parasite density readings was used in analysis. Hemoglobin concentration was 
determined using HemoCue AB (Ängelholm, Sweden). 
Sample size. The sample size for the trial was based on the primary trachoma outcome.13 For the 
malaria outcome, the power calculation was based on malaria estimates from the low 
transmission season.14 We estimated that a random sample of 50 children in 12 communities per 
arm (24 communities total) would provide 80% power to detect a 3% difference in malaria 
parasitemia, assuming a baseline prevalence of 10% and an intraclass correlation coefficient of 
0.075. 
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Statistical analysis. All analyses were conducted as intention-to-treat. To compare malaria 
prevalence between annual and biannual mass azithromycin distribution arms, an unadjusted 
mixed effects logistic regression model was used with a fixed effect for study arm and a random 
effect for community to account for clustering within communities. Parasitemia and hemoglobin 
levels were compared using a linear mixed effects regression model with a fixed effect for study 
arm and a random effect for community. As a sensitivity analysis, we repeated analyses using the 
community-level prevalence of malaria metrics, which does not require assumptions related to 
the structure of the covariance matrix. All P-values were calculated with an exact permutation 
test accounting for the stratified randomization scheme. All analyses were conducted in R 
(version 3.3.1, R Foundation for Statistical Computing, Vienna, Austria). 
RESULTS 
 Of 1,037 children from 24 communities with blood samples for malaria, 511 (49.3%) 
were in the annual mass azithromycin distribution arm and 526 (50.7%) were in the biannual 
mass azithromycin distribution arm (Figure 1). Baseline characteristics between children in 
communities randomized to annual and biannual distribution were well balanced (Table 1). 
Antibiotic coverage among children 6-60 months of age was 88.8% in the annual distribution 
arm and 80.8% in the biannual distribution arm (Table 2). Antibiotic coverage was similar at 
each mass azithromycin distribution time point between the two study arms (Table 2).  
 Malariometric analyses are presented in Table 3. Malaria prevalence in the biannual 
distribution arm was lower than in the annual distribution arm (42.6% versus 50.6%), but this 
difference was not statistically significant in a model accounting for clustering (P=0.29). The 
ICC for malaria parasitemia was 0.10 (95% CI 0.05 to 0.19). We did not detect a difference 
between study arms in mean parasite density (mean parasite density 6,260 in the annual arm 
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versus 10,660 in the biannual arm, P=0.57). Clinical malaria prevalence, defined as the presence 
of parasitemia plus fever, was similar in the biannual and annual arms (5.9% versus 6.8%, 
P=0.69). There was no difference in hemoglobin between the annual and biannual arms (9.2 
g/dL in the annual compared to 9.5 g/dL in the biannual arm, P=0.21). Results were robust to 
analyses at both the community and individual levels (Table 3). 
DISCUSSION 
 After 36 months of biannual mass azithromycin distribution, there was a non-significant 
decrease in malaria parasitemia relative to annual mass azithromycin distribution. In the same 
communities approximately 2 years prior, malaria parasitemia prevalence during the low 
transmission season was significantly lower in communities that had received two mass 
azithromycin distributions compared with those that had received a single mass azithromycin 
distribution (19.5% compared to 29.8%).1 These results are consistent with mathematical 
models, which have suggested that mass drug administration for malaria may be maximally 
effective during the low transmission season.17-19 It is possible that azithromycin is more 
effective at the community level for malaria control during the low transmission season because, 
the probability of reinfection is lower after treatment. A previous study showed a short-term 
reduction (73%) in malaria parasitemia prevalence in communities with low (6% at baseline) 
prevalence following mass azithromycin distribution, but no long-term effect of azithromycin 
distribution at the community level.20 A previous analysis of the PRET Niger study demonstrated 
a non-significant reduction in all-cause mortality with biannual compared to annual azithromycin 
distribution over the 36-month period (O’Brien et al, under review). Given that azithromycin has 
only modest efficacy against P. falciparum21,22, the major cause of malaria in Niger, 
azithromycin may offer incomplete protection against clinical malaria. Azithromycin may have a 
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greater impact on malaria control during the low transmission season compared to the high 
transmission season.                                   
 The results of this study are consistent with previously-reported results from 24 different 
communities randomized to annual versus biannual mass azithromycin distribution over a 36-
month period in the same study.11 In these studies, samples were collected during the high 
transmission season. It is possible that multiple mass azithromycin distributions increase 
selection of azithromycin-resistant strains, although we were unable to assess this here. Previous 
studies have demonstrated mixed results for the effect of azithromycin treatment on the 
development of plasmodium resistance.2,23 Testing azithromycin resistance in plasmodium is 
challenging, and the degree to which resistance could mitigate the protective effects of 
azithromycin is unknown. As tests for azithromycin-resistant malaria become more readily 
available, it will be important to assess the role of azithromycin resistance in malaria in the 
context of mass drug administration. 
The results of this analysis must be considered in the context of several limitations. In the 
annual distribution arm, all individuals in the community were eligible for treatment, whereas 
treatments were targeted to children 12 years of age and under in the biannual arm. It is possible 
that treatment of additional individuals in the community outside of the targeted age range had 
an effect on malaria transmission. Thus, any effect of intervention cannot be attributed solely to 
treatment administration frequency. The WHO coverage target for trachoma control is 80%. Not 
every individual in every community was treated at each time point, and treatment coverage 
tended to be lower for older age groups. Blood samples for malaria testing were only collected at 
12 and 36 months after randomization. We were unable to assess baseline malaria prevalence. In 
addition, baseline data on bed net coverage or use were not available.  These data were collected 
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in very different malaria transmission seasons, so we are unable to measure whether the burden 
of malaria was decreasing over time during ongoing mass azithromycin distribution. As 
expected, malaria parasitemia prevalence was higher in the present report than was noted in the 
same communities previously, likely due to different seasons of data collection. Given that all 
communities received either annual or biannual mass azithromycin distribution and there was no 
untreated comparison group, it may be difficult to detect modest differences in malaria 
parasitemia between communities treated with different frequencies over a three-year period. 
Studies with a comparison group that did not receive azithromycin may be required to fully 
understand the effects of mass azithromycin distribution for malaria control. Larger studies may 
be necessary to detect the effect of azithromycin on malaria parasitemia. 
Biannual mass azithromycin distribution during a three-year period led to a non-
statistically significant decrease in malaria parasitemia during the peak transmission season 
relative to annual mass azithromycin distribution. Although azithromycin has activity against 
malaria during high transmission, any protective effect may be mitigated by high rates of 
reinfection. In trachoma-endemic regions, there may be some collateral benefit of mass 
azithromycin distribution on malaria parasitemia, although more frequent dosing in combination 
with other antimalarials may be required for azithromycin to contribute significantly to malaria 
control in regions with seasonal malaria transmission. 
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FIGURE LEGENDS 
Figure 1. CONSORT flow diagram  
Figure 2. Map of study communities. Communities in the annual distribution arm are in red and 
biannual distribution in blue. Larger circles represent larger total population size.  
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Table 1. Baseline characteristics by randomization arm 
 
 Annual Distribution 
N=12 
Biannual Distribution 
N=12 
No. children age 6-60 months 
per community, mean (range) 141 (44 to 580) 136 (59 to 224) 
Proportion female (95% CI) 51.9% (50.9 to 52.8%) 51.6% (50.1 to 53.1%) 
Prevalence of TF (95% CI) 27.0% (16.0 to 38.0%) 24.7% (16.4 to 32.9%) 
Prevalence of TI (95% CI) 8.7% (4.6 to 12.8%) 9.1% (5.0 to 13.3%) 
Abbreviations: No.: number; 95% CI: 95% confidence interval; TF: trachomatous inflammation – 
follicular; TI: trachomatous inflammation – intense 
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Table 2. Average antibiotic coverage at each mass azithromycin distribution by randomization arm by age group 
 
 6-60 months 5-12 years >12 years 
 Annual  
Distribution 
(95% CI) 
Biannual  
Distribution 
(95% CI) 
Annual  
Distribution 
(95% CI) 
Biannual 
Distribution 
(95% CI) 
Annual  
Distribution 
(95% CI) 
Biannual 
Distribution 
(95% CI) 
Month 0 88.8% (86.1%- 91.5%) 80.8% (76.4%-85.1%) 79.4% (76.2%-82.4%) 71.2% (66.8%-75.2%) 65.8% (62.8%-68.7%) 0.7% (0.3%-1.3%) 
Month 6 -- 78.6% (74.6%-82.6%) -- 57.2% (54.8%-59.4%) -- -- 
Month 12 85.7% (83.2%-88.1%) 81.1% (78.3%-84.0%) 73.2% (69.1%-76.3%) 65.2% (60.1%-69.9%) 62.8% (60.2%-65.5%) 0.3% (0.0%-0.8%) 
Month 18 -- 82.2% (77.2%-87.1%) -- 63.4% (59.2%-67.1%) -- -- 
Month 24 87.2% (84.9%-89.6%) 84.3% (80.1%-88.6%) 75.9% (69.8%-81.4%) 65.4% (59.7%-69.5%) 62.2% (58.8%-65.4%) 0.2% (0.1%-0.4%) 
Month 30 -- 78.2% (74.0%-82.4%) -- 57.1% (52.9%-62.3%) -- -- 
Month 36 79.7% (75.4%-84.0%) 75.8% (71.6%-80.1%) 71.3% (67.7%-73.6%) 61.3% (54.9%-66.6%) 66.8% (59.0%-75.0%) 4.8% (0.2%-15.8%) 
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Table 3. Malariometric outcomes among children aged 6-60 months by randomization arm 
 
 Annual 
Distribution 
Biannual 
Distribution 
P-
value
1 
Mean Difference 
 (95% CI)
2
 
P-
value
2 
Parasitemia 
prevalence (95% 
CI) 
50.6% 
(40.3 to 60.8%) 
42.6% 
(31.7 to 
53.6%) 
0.29 -7.9% (-22.0 to 6.2%) 0.28 
Parasite density, 
mean (95% CI) 
6,260  
(3,730 to 
8,800) 
10,660  
(6,370 to 
14,950) 
0.57 4,985 (-1,309 to 11,229) 0.41 
Clinical malaria3 
prevalence 
(95% CI) 
6.8% 
(4.8 to 9.4%) 
5.9% 
(4.0 to 8.3%) 0.69 
-0.3% (-4.4 to 
3.9%) 0.89 
Hemoglobin, g/dL, 
mean (95% CI) 9.2 (9.1 to 9.4) 9.5 (9.3 to 9.6) 0.21 0.2 (-0.2 to 0.5) 0.70 
1Calculated with an exact permutation test in a mixed effects model with a fixed effect for study arm and 
random effect for community; 2Mean difference in each measure at the community level; 3Defined as 
malaria parasitemia and fever (temperature 38.5C) 
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Figure 1. CONSORT Diagram 
Niger: 6 CSIs in Matameye 
District 
Excluded from analysis (n=211) 
   Not meeting inclusion criteria (n=163) 
   Not randomly selected (n=24) 
   In other study arm (n=24) 
 
 
Clusters analyzed (n=12 communities) 
Participants analyzed  
511 children at 36 months 
Excluded from analysis (n=0 communities) 
 
 
Lost to follow-up, Month 36 (n=0 communities) 
Discontinued intervention, Month 36 (n=0 
communities) 
Annual distribution (n=12 communities) 
Total treated children/total pop (range) 
 Month 0: 1474 (39-467)/4347 (131-1336) 
 Month 6: NA 
 Month 12: 1293 (36-423)/3998 (132-1269) 
 Month 18: NA 
 Month 24: 1355 (35-165)/4214 (127-1388) 
 Month 30: NA 
 Month 36: 1117 (35-364)/4084 (111-1356) 
 Did not receive allocated intervention (n=0) 
Lost to follow-up, Month 36 (n=0 communities) 
Discontinued intervention, Month 36 (n=0 
communities) 
 
Biannual distribution (n=12 communities) 
Total treated children/total pop (range) 
 Month 0: 1334 (41-176)/2243 (71-294) 
 Month 6: 1192 (36-165)/1810 (59-269) 
 Month 12: 1145 (43-160)/1958 (69-286) 
 Month 18: 1217 (36-167)/1975 (59-279) 
 Month 24: 1234 (44-165)/2130 (73-294) 
 Month 30: 1136 (37-153)/1869 (61-246) 
 Month 36: 1049 (28-154)/2089 (48-291) 
 Did not receive allocated intervention (n=0) 
 
Clusters analyzed (n=12 communities) 
Participants analyzed  
526 children at 36 months 
Excluded from analysis (n=0 communities) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 24 
communities) 
Enrollment 
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Figure 2 
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